

Supplementary Table 1: Patients with unknown primary lesions and without immunosuppression have improved survival among patients with stage IIIB and stage IV MCC

Stage IIIB (n = 92)	<u>Univariate analysis</u>			<u>Multivariate analysis</u>		
	HR	95% CI	P	HR	95% CI	P
MCC-specific survival	0.411	0.191 to 0.888	0.024	0.362	0.154 to 0.849	0.021
Overall survival	0.400	0.190 to 0.841	0.016	0.407	0.179 to 0.926	0.032
Recurrence-free survival	0.436	0.230 to 0.826	0.011	0.422	0.205 to 0.865	0.018
Stage IV (n = 19)						
MCC-specific survival	0.278	0.084 to 0.922	0.036	0.230	0.046 to 1.137	0.071
Overall survival	0.278	0.084 to 0.922	0.036	0.198	0.035 to 1.136	0.069
Recurrence-free survival	0.685	0.027 to 1.772	0.436	0.801	0.229 to 2.802	0.728